Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20875905 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2TAAR1GRM2GRM3HTT | |
| SCHEMBL20875891 | 0.90 | GAA (0.38) | SMN1; SMN2HTTGAACACNA1GMEN1 | |
| SCHEMBL8295083 | 0.86 | CTRB1 (0.41) | — | |
| SCHEMBL20875887 | 0.86 | CTRB1 (0.41) | — | |
| SCHEMBL20875888 | 0.86 | CTRB1 (0.41) | — | |
| SCHEMBL20876093 | 0.83 | GAA (0.38) | GAACACNA1GMEN1KMT2A | |
| SCHEMBL20876094 | 0.83 | GAA (0.38) | GAACACNA1GMEN1KMT2A | |
| SCHEMBL22262925 | 0.79 | FPR2 (0.36) | SMN1; SMN2GAACACNA1GMEN1KMT2A | |
| SCHEMBL22263019 | 0.79 | LMNA (0.41) | ALDH1A1POLB | |
| SCHEMBL20875936 | 0.78 | CTRB1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-11-23 | — | — | US | disclosed |
| EP-3692035-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2020-08-12 | — | — | EP | disclosed |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2020-07-30 | — | — | US | disclosed |
| WO-2019068841-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | PLA2G1B, PLA2G4A, PLA2G4C | SMN1; SMN2 504/4885TAAR1 3370/4885GRM2 1704/4885 |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G4A, PLA2G4C | SMN1; SMN2 504/4885TAAR1 3370/4885GRM2 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.